Citigroup’s Adicet Bio ACET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $33.7K | Buy |
+4,721
| New | +$41.2K | ﹤0.01% | 4833 |
|
|
2025
Q4 | – | Sell |
-10
| Closed | -$134 | – | 6012 |
|
|
2025
Q3 | $134 | Sell |
10
-34
| -77% | -$401 | ﹤0.01% | 5790 |
|
|
2025
Q2 | $432 | Sell |
44
-99
| -69% | -$1.04K | ﹤0.01% | 5449 |
|
|
2025
Q1 | $1.73K | Buy |
143
+128
| +853% | +$1.83K | ﹤0.01% | 5349 |
|
|
2024
Q4 | $232 | Sell |
15
-9
| -38% | -$170 | ﹤0.01% | 5657 |
|
|
2024
Q3 | $553 | Sell |
24
-470
| -95% | -$10.5K | ﹤0.01% | 5476 |
|
|
2024
Q2 | $9.6K | Sell |
494
-184
| -27% | -$4.93K | ﹤0.01% | 5154 |
|
|
2024
Q1 | $25.5K | Buy |
678
+336
| +98% | +$13.9K | ﹤0.01% | 4956 |
|
|
2023
Q4 | $10.4K | Buy |
342
+293
| +598% | +$6.39K | ﹤0.01% | 5188 |
|
|
2023
Q3 | $1.08K | Sell |
49
-1,598
| -97% | -$56.4K | ﹤0.01% | 5085 |
|
|
2023
Q2 | $64K | Buy |
1,647
+1,586
| +2,600% | +$140K | ﹤0.01% | 4500 |
|
|
2023
Q1 | $5.59K | Sell |
61
-4,942
| -99% | -$620K | ﹤0.01% | 4915 |
|
|
2022
Q4 | $716K | Sell |
5,003
-2,504
| -33% | -$625K | ﹤0.01% | 2913 |
|
|
2022
Q3 | $1.71M | Buy |
7,507
+7,311
| +3,730% | +$1.86M | ﹤0.01% | 2270 |
|
|
2022
Q2 | $46K | Buy |
196
+74
| +61% | +$16.2K | ﹤0.01% | 4569 |
|
|
2022
Q1 | $39K | Sell |
122
-271
| -69% | -$62.3K | ﹤0.01% | 4831 |
|
|
2021
Q4 | $110K | Buy |
393
+128
| +48% | +$22K | ﹤0.01% | 4681 |
|
|
2021
Q3 | $33K | Buy |
265
+82
| +45% | +$10.2K | ﹤0.01% | 4977 |
|
|
2021
Q2 | $30K | Sell |
183
-548
| -75% | -$112K | ﹤0.01% | 5075 |
|
|
2021
Q1 | $153K | Buy |
731
+7
| +1% | +$1.61K | ﹤0.01% | 4155 |
|
|
2020
Q4 | $163K | Buy |
724
+705
| +3,711% | +$144K | ﹤0.01% | 5142 |
|
|
2020
Q3 | $4K | Sell |
19
-1
| -5% | -$253 | ﹤0.01% | 7089 |
|
|
2020
Q2 | $5K | Sell |
20
-38
| -66% | -$7.47K | ﹤0.01% | 7250 |
|
|
2020
Q1 | $7K | Buy |
58
+5
| +9% | +$742 | ﹤0.01% | 7148 |
|
|
2019
Q4 | $9K | Buy |
53
+41
| +342% | +$20.8K | ﹤0.01% | 7228 |
|
|
2019
Q3 | $12K | Sell |
12
-30
| -71% | -$33.5K | ﹤0.01% | 6975 |
|
|
2019
Q2 | $48K | Buy |
42
+21
| +100% | +$19K | ﹤0.01% | 6514 |
|
|
2019
Q1 | $16K | Buy |
21
+8
| +62% | +$7.27K | ﹤0.01% | 7053 |
|
|
2018
Q4 | $12K | Sell |
13
-6
| -32% | -$7.9K | ﹤0.01% | 7080 |
|
|
2018
Q3 | $32K | Buy |
19
+7
| +58% | +$9.13K | ﹤0.01% | 6846 |
|
|
2018
Q2 | $12K | Hold |
12
| – | – | ﹤0.01% | 7108 |
|
|
2018
Q1 | $13K | Buy |
+12
| New | +$22K | ﹤0.01% | 6931 |
|
Other funds holding ACET
AW
Citigroup's ACET Position: Q3 2026 in Review
Citigroup opened a new position in Adicet Bio (ACET) in Q3 2026: 4,721 shares worth $33.7K. The stake represents ﹤0.01% of the portfolio and ranks #4833 among its holdings. This is a return to the name: Citigroup previously reported a position in ACET as recently as Q3 2025.
Citigroup first reported a position in ACET in Q1 2018 and has held it in 32 quarters since. The position peaked at $1.71M in Q3 2022. 13 funds tracked by Wall St. Rank hold ACET as of Q3 2026.
- Citigroup held 4,721 shares of Adicet Bio worth $33.7K as of Q3 2026.
- Adicet Bio was a new Citigroup position in Q3 2026.
- Adicet Bio made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4833 holding.
- Citigroup first reported a position in Adicet Bio in Q1 2018 and has held it in 32 quarters since.
- Citigroup's Adicet Bio position peaked at $1.71M in Q3 2022.
- 13 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.